Advertisement

Effect of probiotics supplementation on glucose and oxidative stress in type 2 diabetes mellitus: a meta-analysis of randomized trials

  • Edris Ardeshirlarijani
  • Ozra Tabatabaei-Malazy
  • Shahrzad Mohseni
  • Mostafa Qorbani
  • Bagher LarijaniEmail author
  • Reza Baradar Jalili
Review article

Abstract

Purpose

The role of oxidative stress in pathogenesis of diabetes is well established. In addition, an association between gut microbiota and type 2 diabetes mellitus (T2DM) is widely observed in previously published reports. This meta-analysis critically examines the association between gut microbiota, and oxidative stress in T2DM.

Methods

A systematic search for clinical trials was performed in PubMed, Web of Science and Scopus web databases up to 1 Jan 2019. Primary search terms include “microbiota”, “diabetes”, and “oxidative stress”. Study was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline. All clinical trials that compared the effects of probiotic supplementations with a control group using end points serum levels of fasting blood sugar (FBS), hemoglobin A1C (HbA1C) and oxidative stress biomarkers were included. Two independent researchers screened the data extracted from the relevant studies. The pooled standardized mean difference (SMD) was estimated using the random or fixed effects model. Heterogeneity among the studies was assessed using Q-test.

Results

Overall, 13 randomized clinical trials (RCTs) involving 840 subjects with T2DM were included in the meta-analysis. The analysis showed that probiotics intake resulted in significant improvement in serum levels of FBS [SMD: -0.35, 95% CI: (−0.59, −0.12)], total antioxidant status (TAS) [SMD: 0.33, 95% CI: (0.11, 0.55)], total glutathione (GSH) [SMD: 0.41, 95% CI: (0.26, 0.56)] and malondialdehyde (MDA) [SMD: -0.54, 95% CI: (−0.83, −0.26)]. No significant improvement was found in HbA1C [SMD: -0.06, 95% CI:(−0.82, 0.69)], and nitric oxide (NO) [SMD:-0.24, 95% CI:(−1.10, 0.62)] levels.

Conclusion

It seems that gut microbiota can exert beneficial effects in diabetic patients via altering oxidative stress’ biomarkers. The beneficial effect of gut microbiota however was modest on FBS and non-significant on HbA1C. These results need to be confirmed by conducting more reliable RCTs.

PROSPERO Registration number

CRD42019134905.

Graphical abstract

Flow diagram of the study selection process.

Keywords

Diabetes mellitus type 2 gut microbiota oxidative stress 

Notes

Acknowledgements

This research has been supported by Tehran University of Medical Sciences & health services grant numbered 39856-192-03-97. All of authors thank the TUMS for its financial support.

Authors’ contributions

OTM and EAL did literature bibliography, reviewed data, wrote draft and conceived the paper. SHM and RBJ did literature bibliography, and drafted some parts of the paper. MQ reviewed data, conducted meta-analysis, and drafted the paper. BL conceived, supervised, and edited the paper. All authors read and approved the final manuscript.

Funding

This research has been supported by Tehran University of Medical Sciences & health services grant numbered 39856–192–03-97. The funder had no role in any part of study; design, data collection, analysis, interpretation or writing.

Compliance with ethical standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

40199_2019_302_MOESM1_ESM.docx (13 kb)
ESM 1 (DOCX 13 kb)

References

  1. 1.
    IDF diabetes atlas, 8th edition 2017. Available at: www.IDF.org/e-library/epidemiology-research/diabetes-atlas.html. Last available: 22 May 2019.
  2. 2.
    Gomes AC, Bueno AA, de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr J. 2014;13:60.  https://doi.org/10.1186/1475-2891-13-60.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hu FB. Globalization of Diabetes: The role of diet, lifestyle, and genes. Diabetes Care. 2011;34:1249–57.CrossRefGoogle Scholar
  4. 4.
    Bordalo Tonucci L, Dos Santos KM. De Luces Fortes Ferreira CL, Ribeiro SM, De Oliveira LL, Martino HS. Gut microbiota and probiotics: Focus on diabetes mellitus. Crit Rev Food Sci Nutr. 2017;57:2296–309.  https://doi.org/10.1080/10408398.2014.934438.CrossRefPubMedGoogle Scholar
  5. 5.
    Hansen AK, Hansen CH, Krych L, Nielsen DS. Impact of the gut microbiota on rodent models of human disease. World J Gastroenterol. 2014;20:17727–36.CrossRefGoogle Scholar
  6. 6.
    Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008;7:123–9.CrossRefGoogle Scholar
  7. 7.
    Thomas LV, Ockhuizen T, Suzuki K. Exploring the influence of the gut microbiota and probiotics on health: a symposium report. Br J Nutr. 2014;112(Suppl 1):S1–18.  https://doi.org/10.1017/S0007114514001275.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Quigley EM. Gut bacteria in health and disease. Gastroenterol Hepatol (N Y). 2013;9:560–9.Google Scholar
  9. 9.
    Hartstra AV, Bouter KE, Backhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015;38:159–65.CrossRefGoogle Scholar
  10. 10.
    Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab. 2013;63:1–9.CrossRefGoogle Scholar
  11. 11.
    FAO and WHO. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. Guidelines for evaluation of probiotics in food. London, Ontario, Canada. 2002. Available at: http://www.who.int/foodsafety/publications/fs_management/probiotics2/en/
  12. 12.
    Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics-approaching a definition. The Am J clin Nutr. 2001;73(2 Suppl):361s–4s.CrossRefGoogle Scholar
  13. 13.
    Rajkumar H, Mahmood N, Kumar M, Varikuti SR, Challa HR, Myakala SP. Effect of probiotic (VSL# 3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial. Mediat Inflamm. 2014;2014:348959.  https://doi.org/10.1155/2014/348959.CrossRefGoogle Scholar
  14. 14.
    Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012;28:539–43.CrossRefGoogle Scholar
  15. 15.
    Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365–73.CrossRefGoogle Scholar
  16. 16.
    Tabatabaei-Malazy O, Nikfar S, Larijani B, Abdollahi M. Influence of ascorbic acid supplementation on type 2 diabetes mellitus in observational and randomized controlled trials; a systematic review with meta-analysis. J Pharm Pharm Sci. 2014;17:554–82.CrossRefGoogle Scholar
  17. 17.
    Khodaeian M, Tabatabaei-Malazy O, Qorbani M, Farzadfar F, Amini P, Larijani B. Effect of vitamins C and E on insulin resistance in diabetes: a meta-analysis study. Eur J Clin Investig. 2015;45:1161–74.  https://doi.org/10.1111/eci.12534.CrossRefGoogle Scholar
  18. 18.
    Tabatabaei-Malazy O, Larijani B, Abdollahi M. A systematic review of in vitro studies conducted on effect of herbal products on secretion of insulin from Langerhans islets. J Pharm Pharm Sci. 2012;15:447–66.CrossRefGoogle Scholar
  19. 19.
    Uskova MA, Kravchenko LV. Antioxidant properties of lactic acid bacteria--probiotic and yogurt strains. Vopr Pitan. 2009;78:18–23.PubMedGoogle Scholar
  20. 20.
    Mikelsaar M, Zilmer M. Lactobacillus fermentum ME-3- an antimicrobial and antioxidative probiotic. Microb Ecol Health Dis. 2009;21(1):1–27.CrossRefGoogle Scholar
  21. 21.
    Yadav H, Jain S, Sinha PR. Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J Dairy Res. 2008;75:189–95.CrossRefGoogle Scholar
  22. 22.
    Mazloom Z, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci. 2013;38:38–43.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.  https://doi.org/10.1136/bmj.b2535.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.CrossRefGoogle Scholar
  25. 25.
    Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14(5):951–7.  https://doi.org/10.1111/j.1365-2753.2008.00986.x.CrossRefPubMedGoogle Scholar
  26. 26.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefGoogle Scholar
  27. 27.
    Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr. 2014;33:198–203.CrossRefGoogle Scholar
  28. 28.
    Asemi Z, Alizadeh SA, Ahmad K, Goli M, Esmaillzadeh A. Effects of beta-carotene fortified synbiotic food on metabolic control of patients with type 2 diabetes mellitus: A double-blind randomized cross-over controlled clinical trial. Clin Nutr. 2016;35:819–25.CrossRefGoogle Scholar
  29. 29.
    Bahmani F, Tajadadi-Ebrahimi M, Kolahdooz F, Mazouchi M, Hadaegh H, Jamal AS, et al. The consumption of synbiotic bread containing lactobacillus sporogenes and inulin affects nitric oxide and malondialdehyde in patients with type 2 diabetes mellitus: randomized, double-blind, placebo-controlled trial. J Am Coll Nutr. 2016;35(6):506–13.CrossRefGoogle Scholar
  30. 30.
    Miraghajani M, Zaghian N, Mirlohi M, Feizi A, Ghiasvand R. The impact of probiotic soy milk consumption on oxidative stress among type 2 diabetic kidney disease patients: a randomized controlled clinical trial. J Ren Nutr. 2017;27(5):317–24.CrossRefGoogle Scholar
  31. 31.
    Soleimani A, Zarrati Mojarrad M, Bahmani F, Taghizadeh M, Ramezani M, Tajabadi-Ebrahimi M, et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney Int. 2017;91(2):435–42.CrossRefGoogle Scholar
  32. 32.
    Tonucci LB. Olbrich Dos Santos KM, Licursi de Oliveira L, Rocha Ribeiro SM, Duarte Martino HS. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin Nutr. 2017;36(1):85–92.CrossRefGoogle Scholar
  33. 33.
    Mafi A, Namazi G, Soleimani A, Bahmani F, Aghadavod E, Asemi Z. Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. Food Funct. 2018;9(9):4763–70.  https://doi.org/10.1039/c8fo00888d.CrossRefPubMedGoogle Scholar
  34. 34.
    Mazruei Arani N, Emam-Djomeh Z, Tavakolipour H, Sharafati-Chaleshtori R, Soleimani A, Asemi Z. The effects of probiotic honey consumption on metabolic status in patients with diabetic nephropathy: a randomized, double-blind, controlled trial. Probiotics Antimicrob Proteins. 2018.  https://doi.org/10.1007/s12602-018-9468-x.
  35. 35.
    Mohseni S, Bayani M, Bahmani F, Tajabadi-Ebrahimi M, Bayani MA, Jafari P, et al. The beneficial effects of probiotic administration on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial. Diabetes Metab Res Rev. 2018;34(3).  https://doi.org/10.1002/dmrr.2970.
  36. 36.
    Raygan F, Rezavandi Z, Bahmani F, Ostadmohammadi V, Mansournia MA, Tajabadi-Ebrahimi M, et al. The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease. Diabetol Metab Syndr. 2018;10:51.  https://doi.org/10.1186/s13098-018-0353-2.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085.  https://doi.org/10.1371/journal.pone.0009085.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.CrossRefGoogle Scholar
  39. 39.
    Li C, Li X, Han H, Cui H, Peng M, Wang G, et al. Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: A meta-analysis of randomized, controlled trials. Medicine. 2016;95(26):e4088.  https://doi.org/10.1097/MD.0000000000004088.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Hu YM, Zhou F, Yuan Y, Xu YC. Effects of probiotics supplement in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. Med Clin (Barc). 2017;148(8):362–70.  https://doi.org/10.1016/j.medcli.2016.11.036.CrossRefGoogle Scholar
  41. 41.
    Yao K, Zeng L, He Q, Wang W, Lei J, Zou X. Effect of probiotics on glucose and lipid metabolism in type 2 diabetes mellitus: a meta-analysis of 12 randomized controlled trials. Med Sci Monit. 2017;23:3044–53.CrossRefGoogle Scholar
  42. 42.
    Kasinska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a meta-analysis. Pol Arch Med Wewn. 2015;125(11):803–13.PubMedGoogle Scholar
  43. 43.
    Rad AH, Abbasalizadeh S, Vazifekhah S, Abbasalizadeh F, Hassanalilou T, Bastani P, et al. The future of diabetes management by healthy probiotic microorganisms. Curr Diabetes Rev. 2017;13(6):582–9.  https://doi.org/10.2174/1573399812666161014112515.CrossRefPubMedGoogle Scholar
  44. 44.
    Noce A, Marrone G, Di Daniele F, Ottaviani E, Wilson Jones G, Bernini R, et al. Impact of gut microbiota composition on onset and progression of chronic non-communicable diseases. Nutrients. 2019;11(5).  https://doi.org/10.3390/nu11051073.
  45. 45.
    Khan IT, Nadeem M, Imran M, Ullah R, Ajmal M, Jaspal MH. Antioxidant properties of Milk and dairy products: a comprehensive review of the current knowledge. Lipids Health Dis. 2019;18(1):41.  https://doi.org/10.1186/s12944-019-0969-8.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Chamari M, Djazayery A, Jalali M, Sadrzadeh Yeganeh H, Hosseini S, et al. The effect of daily consumption of probiotic and conventional yoghurt on some oxidative stress factors in plasma of young healthy women. ARYA Atheroscler J. 2008;4:175–9.Google Scholar
  47. 47.
    Sotoudegan F, Daniali M, Hassani S, Nikfar S, Abdollahi M. Reappraisal of probiotics' safety in human. Food Chem Toxicol. 2019;129:22–9.  https://doi.org/10.1016/j.fct.2019.04.032.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Edris Ardeshirlarijani
    • 1
  • Ozra Tabatabaei-Malazy
    • 2
    • 3
  • Shahrzad Mohseni
    • 3
  • Mostafa Qorbani
    • 4
  • Bagher Larijani
    • 3
    Email author
  • Reza Baradar Jalili
    • 5
  1. 1.Simon Fraser UniversityBurnabyCanada
  2. 2.Non-Cummunicable Diseases Research Center, Endocrinology and Metabolism Population Sciences InstituteTehran University of Medical SciencesTehranIran
  3. 3.Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences InstituteTehran University of Medical SciencesTehranIran
  4. 4.Non-communicable Diseases Research CenterAlborz University of Medical SciencesKarajIran
  5. 5.Department of SurgeryUniversity of British ColumbiaVancouverCanada

Personalised recommendations